The current surge in the XBI index is not a sign of an overvalued market. Unlike frothy periods where all stocks rise, this rally is supported by strong fundamentals like FDA permissiveness and M&A activity, while still allowing for stock-picking differentiation between winners and losers.

The first quarter of 2026 marked a 10-year high for the quantity of public biotech acquisitions, with nine deals announced. While the total dollar value of $32 billion is typical, the high frequency indicates broad-based demand from pharma and a healthy, active M&A market that can recycle capital back into the industry.

The recent biotech market upswing isn't just a reaction to broader economic shifts. It's fundamentally supported by greater clarity on drug pricing, successful commercial launches by biotech firms, and a strong M&A environment, indicating robust industry health.

Over $22.8 billion from M&A deals in the first half of the year was returned to specialist biotech investors. This capital is being rapidly redeployed back into the sector, creating a significant tailwind that can explain otherwise news-free stock jumps in various biotech companies.

The annual J.P. Morgan Healthcare Conference carries high expectations for major M&A announcements. A failure to deliver significant deal news could deflate the market's recent positive momentum. This could trigger a 'late winter lull,' creating a precarious situation just as a new wave of private companies prepares to go public, potentially overwhelming investor demand.

Investors feared a market sell-off if the anticipated wave of M&A didn't materialize in early January. However, the sector traded well despite a slow start, demonstrating underlying strength and investor confidence that wasn't solely dependent on acquisition hype, which was a very encouraging sign for the market.

Neurocrin's acquisition of Soleno keeps a profitable, commercial-stage asset within the biotech sector (and the XBI ETF), rather than transferring its cash flow to Big Pharma. This trend of profitable biotechs acquiring others makes the sector more attractive to generalist investors who prioritize cash flow, potentially driving valuations.

Contrary to expectations, a quiet M&A period at a major event like the J.P. Morgan conference can be positive. It indicates that biotech companies are well-capitalized and not pressured to sell, shifting leverage from buyers to sellers and reflecting underlying strength in the sector.

A healthy biotech IPO market won't reappear independently. It requires a robust M&A landscape first, which attracts generalist investors back to the sector and provides the necessary market liquidity to successfully support new public offerings.